Yuichiro Kikawa

Hirakata, 5731191, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 79 publications

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

SERENA-6 visual patient-reported outcomes and safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapy.

Journal: The oncologist

Published: May 22, 2026

Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness).

Real-world uptake of gBRCA testing as a companion diagnostic for olaparib in patients with high-risk HER2-negative early breast cancer in Japan: a cross-sectional multicenter study (BRCAwareness).

Journal: Breast cancer (Tokyo, Japan)

Published: March 24, 2026

Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.

Early-Onset Direct Antiglobulin Test-Negative Autoimmune Hemolytic Anemia Induced by Pembrolizumab in Perioperative Triple-Negative Breast Cancer: A Case Report.

Journal: Case reports in oncology

Published: March 13, 2026

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: February 12, 2026

Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.

Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial.

Journal: Breast cancer (Tokyo, Japan)

Published: February 12, 2026

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Journal: Breast cancer research : BCR

Published: February 02, 2026

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Journal: American journal of respiratory and critical care medicine

Published: January 25, 2026

Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.

Efficacy of olanzapine for prophylaxis of delayed chemotherapy-induced nausea and vomiting in patients with breast cancer receiving dose-dense AC with a steroid-sparing regimen: a single-center pilot study.

Journal: BMC cancer

Published: January 16, 2026

Supportive cancer care and patient satisfaction: international prospective longitudinal study - secondary data analysis.

Supportive cancer care and patient satisfaction: international prospective longitudinal study - secondary data analysis.

Journal: BMJ supportive & palliative care

Published: December 02, 2025

Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.

Prospective observational study of atezolizumab plus nab-paclitaxel in patients with metastatic triple-negative breast cancer: JBCRG-C08/ATTRIBUTE.

Journal: NPJ breast cancer

Published: November 03, 2025

Patient-Reported Outcomes in Thoracic Surgery: An International Survey of European Society of Thoracic Surgeons (ESTS) and Japanese Association for Chest Surgery (JACS) Members.

Patient-Reported Outcomes in Thoracic Surgery: An International Survey of European Society of Thoracic Surgeons (ESTS) and Japanese Association for Chest Surgery (JACS) Members.

Journal: European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery

Published: September 30, 2025

Showing 1-12 of 79

Last Updated: 09/26/2026